StreetInsider.com News Articles

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274

Tue, 13 Oct 2026 08:00:00 -0400

ORLANDO, Fla., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), announced today that it has seen 272,671 NTRBW warrants exercised at a strike price of $6.43 for proceeds to the company of $1,753,274.53. NTRBW warrants expired on September 30 with no extension. The Company has no remaining tradeable warrants.

The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fentanyl has the potential to become the world's first opioid patch with abuse deterrent properties and is estimated it

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274

Tue, 13 Oct 2026 08:00:00 -0400

Nutriband files patent to extend AVERSA abuse-deterrent protection to 2046

Thu, 08 Oct 2026 07:01:35 -0400

Nutriband Inc. (NASDAQ: NTRB) has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office to expand intellectual property protection for its AVERSA™ transdermal abuse-deterrent technology, the company announced Oct. 8, 2026.

The application covers improved aversive formulations and coating application methods designed to enhance the abuse-deterrent properties of the AVERSA™ technology. If granted, the patent could extend worldwide protection for AVERSA™-based products, including AVERSA™ Fentanyl, to 2046, based on the standard 20-year statutory term from the non-provisional filing date.

AVERSA™ technology uses a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental

Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology

Thu, 08 Oct 2026 07:00:00 -0400

Nutriband files new non-provisional patent application to strengthen intellectual property protection of its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.

Nutriband’s AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.

ORLANDO, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) today announced that it has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office (USPTO) to further strengthen Nutriband’s intellectual property protection for its AVERSA™ abuse deterrent transdermal

Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology

Thu, 08 Oct 2026 07:00:00 -0400

Nutriband’s AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.

Nutriband marks five years on Nasdaq as AVERSA IND filing nears

Thu, 01 Oct 2026 16:05:32 -0400

Nutriband Inc. (NASDAQ: NTRB) marked the fifth anniversary of its listing on the Nasdaq Capital Market on October 1, 2026, with CEO Gareth Sheridan publishing a letter to shareholders reviewing milestones since the company's October 1, 2021 uplisting.

The 2021 uplisting was accompanied by an underwritten public offering that raised $6.6 million, with total gross proceeds of approximately $8.7 million including a concurrent offering. The five-year tradeable warrants issued at that time, traded under the symbol NTRBW, expired as scheduled on September 30, 2026, and have been removed from Nasdaq.

Since uplisting, Nutriband's lead product, AVERSA Fentanyl, has progressed from a feasibility

Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders

Thu, 01 Oct 2026 16:05:00 -0400

Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary

CEO letter reflects on five years of milestones since the Company's October 1, 2021 uplisting, as AVERSA™ Fentanyl advances toward an IND filing and the 2021 offering warrants expire as scheduled

ORLANDO, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) today announced that CEO Gareth Sheridan has published a letter to shareholders marking the fifth anniversary of the Company's listing on the Nasdaq Capital Market, which took effect on October 1, 2021. The letter reviews the key milestones achieved between October 1,

Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders

Thu, 01 Oct 2026 16:05:00 -0400

Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary

Form 25-NSE NutriBand Inc. Filed by: Nasdaq Stock Market LLC

Wed, 30 Sep 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260930/27128787.html

Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis